A Summary & Review of Carnesi’s Latest Release
Most books about invention tell you about the ones that won. Eyewatch, Kenneth Carnesi Sr.’s account of the birth, near-disappearance, and quiet vindication of the EyeWatch biometric authentication patents, tells you about one that got there first and still mattered, even after the money ran out. That’s the pitch, and the book delivers on it.
The story starts in May 2014, in a small office in Garden City, New York. Carnesi, a lawyer with an international banking certificate from Harvard Law and entrepreneurship training from Wharton, had no engineering background. What he had was a diagnosis: the entire financial system was authenticating people with things they carried or things they knew — cards, PINs, signatures — all of which can be stolen, guessed, or forged. The only thing that can’t be faked is something you actually are. Working from that insight, he filed two patent applications one day apart, describing a full architecture for using iris recognition to stop financial fraud across card-present transactions, card-not-present transactions, ATM withdrawals, and wire transfers, with the eye converted into an encrypted mathematical value rather than stored as a raw image.
To turn that diagnosis into a filing, he partnered with Monkeetech, a New York technology company run by his cousins Jeffrey Dinardo Sr. and Jr., who stepped in during a genuinely difficult period in Carnesi’s life. That partnership is one of the more affecting threads in the book — not a garage full of engineers chasing a demo, but family showing up for family, translating a compliance instinct into something the USPTO could actually examine.
Then comes the part most business books skip entirely: the applications went abandoned. Not rejected on the merits — abandoned, because responding to the USPTO’s office actions costs real legal money, and a solo inventor backed by a small technology company couldn’t sustain the prosecution costs that a Mastercard or Samsung legal department would treat as routine. Carnesi doesn’t dress this up. He calls it what it is: a brutal, common, and rarely discussed economic reality of the patent system, one that claims a meaningful share of early-stage innovation every year.
Here’s where the book earns its title and its argument. An abandoned application doesn’t vanish — it stays in the USPTO’s public record as prior art. Years later, when Mastercard, Samsung, Worldpay, and Sony were filing their own biometric authentication patents, their examiners searched the relevant classification codes and found the EyeWatch filings sitting there, specific enough to be relevant to the novelty determinations on their own applications. All four companies ended up citing EyeWatch in the course of their own patent prosecution.
It would have been easy for the book to oversell that, and to its credit, it doesn’t — that restraint is actually one of its strengths. Carnesi is careful, almost lawyerly, about what a prior art citation does and doesn’t mean: it’s not an endorsement, it’s not proof anyone copied him, it’s not a payday. What it does mean is precise and still remarkable — that the patent examiners charged with protecting the novelty of some of the largest technology and payments companies in the world looked at what one man wrote down in 2014 and had to formally account for it before they could proceed. That’s not a participation trophy. That’s the system confirming, four separate times, that the territory had already been mapped. Getting cited once by a company like Mastercard is notable. Getting cited by Mastercard, Samsung, Worldpay, and Sony is the kind of pattern that’s hard to write off as coincidence, and the book is right not to undersell it.
What makes Eyewatch more than a vindication narrative is that it’s also genuinely instructive. Each chapter pairs the historical story with a practical takeaway, and Carnesi clearly wants readers to walk away able to do something, not just admire what he did. There’s a full chapter that walks through, step by step, how to search Google Patents for a competitor’s filings, trace their backward citations, and figure out what territory in your own field is already mapped versus genuinely open. There’s a plain-language explanation of the difference between an anticipation rejection and an obviousness rejection — the kind of distinction that usually costs several hundred dollars an hour to have explained by an attorney. There’s a concrete case for the provisional patent application as a low-cost way to establish a priority date, for under two hundred dollars in USPTO fees, aimed squarely at anyone sitting on an idea they’ve been too intimidated or too broke to protect. Illustrative scenarios throughout — a hospital administrator, a fintech patent analyst — help the mechanics of prior art land as something a non-specialist reader can actually picture doing.
There’s also a quietly impressive detail buried in the technical description that the book makes sure readers don’t skim past: the EyeWatch design converted a scanned iris into an encrypted mathematical value and defaulted to on-device storage rather than retaining the raw image, with enrollment under the user’s own control. That’s a privacy architecture that predates, by years, the kind of biometric data protections that regulators would eventually require. Carnesi doesn’t claim he anticipated a specific law. He makes the more interesting and more defensible point that getting the privacy design right the first time, before anyone was mandating it, is its own form of being early — and that it held up under later legal scrutiny without needing to be revised.
The throughline that ties the whole book together is what Carnesi calls the compliance mindset: the idea that his real advantage was never technical; it was diagnostic. He wasn’t the person who could build the iris scanner. He was the person who, from years spent inside law, banking, and regulatory compliance, could see that fraud was a verification problem wearing a technology costume. That same lens, the book shows, followed him well past EyeWatch — into his work as Chief Operating Officer and Director of Government Sales at Anaptyx, LLC, overseeing its government contracts and regulatory compliance divisions; into his writing on bulk Wi-Fi infrastructure; and eventually into a string of recognitions that arrived, fittingly, all at once in 2026, including BizRecap naming him the country’s Top Biometric Authentication Innovator, more than a decade after the original filings.
That decade-plus gap is really the emotional center of the book, and it’s handled with more honesty than most success narratives allow themselves. Carnesi isn’t shy about the fact that this isn’t a garage-to-IPO story. There’s no acquisition, no licensing windfall, no moment where the inventor gets a check. He’s explicit that the applications never issued as patents and never generated a dollar in royalties. What the book argues, and argues well, is that recognition and financial reward aren’t the same thing, and that a documented, precisely written idea has a durability that doesn’t depend on either one. The record sat quietly in a public database for over ten years, and then it mattered enormously, all at once, without anyone pushing it. That’s a genuinely different way of thinking about what it means to be first, and it’s a rare business book that manages to make an anticlimax feel like the actual point.
One caveat worth naming: this is as much a professional memoir and a how-to guide as it is a history of EyeWatch specifically. Readers looking purely for a blow-by-blow account of the technology may find some later chapters, particularly the ones on career-building and professional visibility, pull further from the patent story than the title suggests. But that’s also what makes the book useful rather than merely interesting. It isn’t asking readers to admire someone else’s story from a distance. It’s asking them to look at their own field, their own overlooked observation, and consider what would happen if they wrote it down precisely and filed it before talking themselves out of it.
Eyewatch works because it tells a true story that most industries have a version of and rarely put on paper: the person who was right first didn’t have the resources to hold the position and turned out to matter anyway. Four of the largest names in payments and technology had to formally account for one man’s filing from a small office in Garden City, New York. The book earns the right to say so plainly. Readers curious about patents, biometrics, compliance, or simply what it looks like to be early and unrewarded and still, eventually, vindicated, will find it a fast, well-argued, and quietly compelling read.
